all report title image
  • Published On : Jun 2022
  • Code : CMI5064
  • Industry : Food and Beverages
  • Pages : 120
  • Formats :

The composition of the human milk contains three major types of HMOs: acid, neutral, and fucosyl. Each is based on the lactose molecule. Lactose synthase is a complex enzyme, composed of two proteins: alpha-lactalbumin and beta-1, 4-galactosyltransferase. The B4GALT1 gene codes for two enzymatic forms of the protein. The richness of Human Milk Oligosaccharides (HMOs) has attracted scientists to their study. These complex sugars, present in mother's milk, are believed to support an infant's immune system and strengthen the gut barrier by blocking pathogens. As such, they are an exciting central area of infant nutrition research. This article explores their benefits and mechanisms of action in infants, including their anti-adhesive properties and effects on bacterial flora development.

Market Statistics:

The global Human Milk Oligosaccharides market was valued at US$ 152.41 Mn in 2021 and is forecast to reach a value of US$ 612.0 Mn by 2030 at a CAGR of 19.65% between 2021 and 2030.

North America held dominant position in the global Human Milk Oligosaccharides market in 2021, accounting for 38.5% share in terms of volume, followed by Europe and Asia Pacific, respectively.

Figure 1. Global Human Milk Oligosaccharides Market Value Share (%), By Region, 2021

Human Milk Oligosaccharides  | Coherent Market Insights

Recent Developments:

  1. In September 2021, Chr Hansen has signed an agreement with industrial biotechnology company Jennewein Biotechnologie to acquire its complete stake in a EUR 310 million deal; Jennewein is involved in the production of human milk oligosaccharides (HMOs) and rare monosaccharides such as L-Fucose and Sialic acid.
  2. In March 2021, BASF announced that PREBILAC, BASF’s brand of 2’-FL, had received approval from the Australia’s Therapeutic Goods Administration (TGA), making it the first and only 2’-FL ingredient to receive TGA approval as a prebiotic ingredient.
  3. In May 2019, BASF SE and Glycosyn signed a partnership agreement for the development and commercialization of human milk oligosaccharides (HMOs) for broad use in dietary supplements, functional nutrition, and medical food. The strategic partnership includes exclusive license of Glycosyn´s patent portfolio for gut health beyond infant nutrition to BASF SE.
CMI table icon

Human Milk Oligosaccharides Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2021: US$ 152.41 Mn
Historical Data for: 2017 to 2021 Forecast Period: 2021 to 2030
Forecast Period 2022 to 2030 CAGR: 19.65% 2030 Value Projection: US$ 612.0 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Application: Infant Formula, Dietary Supplements, Functional Food and Beverage
Companies covered:

ZuChem Inc., Merck & Co. Inc., Chr. Hansen Holding AS (Jennewein Biotechnologie GmbH), Royal FrieslandCampina NV, BASF, IFF (DuPont Nutrition & Health), Gnubiotics, Inbiose NV, Carbosynth Holdings Limited, and Royal DSM N.V

Growth Drivers:
  • Growing awareness regarding health benefits of HMO
  • Launch of new product
Restraints & Challenges:
  • Growing initiatives to promote breastfeeding

Market Drivers:

Growing awareness regarding health benefits of HMO is driving growth of the human milk oligosaccharides market. HMO research (clinical and preclinical) suggests that specific HMOs at the correct level of supplementation can provide babies with unique health benefits. In particular, Human Milk Oligosaccharide supports immunity and gut health, with a potential role in cognitive development, which may open future innovation opportunities and thus, would increase the demand of HMOs globally.

New product launch is another key factor propelling growth of the market. For instance, in November 2021, Abbott launched its most innovative infant formula yet, Similac Pro-Advance® with 2'-Fucosyllactose Oligosaccharide† (2'-FL†), which is the first product in Canada with this breakthrough ingredient in infant formula.

Figure 2. Human Milk Oligosaccharides Market Value Share (%), By Application, 2021

Human Milk Oligosaccharides  | Coherent Market Insights

Market Restraints:

Growing government initiatives to encourage breastfeeding over formula feeding is expected to hinder the growth of the market. The US Dietary Guidelines for Americans and the American Academy of Pediatrics recommend exclusive breastfeeding alert icons for about six months and then continuing breastfeeding while introducing complementary foods alert icons until your child is 12 months old or older. Health experts believe breast milk is the best nutritional choice for infants. The natural breastfeeding HMOs provide the child with ideal nutrition and supports growth and development more than the artificial synthesized HMOs.

Market Opportunities:

Increasing adoption of strategic partnership and agreement among key players is projected to bring lucrative growth opportunities. For instance, in 2021, Royal DSM, acquired Glycom, one of the suppliers of Human Milk Oligosaccharides (HMO), for an enterprise value of USD 765 million. Through the acquisition, DSM could increase the growth of Glycom by offering HMO products under the "Early Life Nutrition" segment, and further could accelerate the HMO product development of Glycom by leveraging its R&D platform and clinical competencies to support Glycom's development of next-generation HMOs.

Growing focus of key manufacturer to increase the production of HMO is also projected to offer significant growth opportunities. For instance, in November 2021, Kyowa Hakko, an international health ingredient manufacturer, established a new facility to manufacture human milk oligosaccharides (HMOs) in Thailand. The company aimed to establish an industrial-scale HMO production system, and the application of this system would be the company's medium- to long-term growth strategy, as it planned to supply HMOs to other companies and utilize the facility for its own product development.

Market Trends/Key Takeaways:

Growing trend of non-genetically modified human milk oligosaccharides is expected to propel growth of the market growth. The consumers are becoming more food-conscious and are looking for clean label non-genetically modified ingredients which are made from sustainable, natural sources. This increased demand for non-GMO products have created a promising opportunity for the HMO manufactures to create a proprietary process for the scalable production of a non-GMO human milk oligosaccharide (HMO) to boost their sales.

Increasing demand for clean label ingredients is again projected to foster market growth. For instance, in August 2021, Congara introduced   non- genetically modified HMO 2’- fucosyllactose (2’FL). The company focused on using synthetic biology tools to develop high-quality, sustainable nature-based products through systems of manufacturing on a molecular level and fermentation basis.

Competitive Landscape:

      1. ZuChem Inc.
      2. Merck & Co. Inc.
      3. Chr. Hansen Holding AS (Jennewein Biotechnologie GmbH)
      4. Royal FrieslandCampina NV
      5. BASF
      6. IFF (DuPont Nutrition & Health)
      7. Gnubiotics
      8. Inbiose NV
      9. Carbosynth Holdings Limited
      10. Royal DSM N.V

A major role in the infant's development is played by human milk oligosaccharides, which are structurally complex glycans found in breast milk. Human milk oligosaccharides (HMOs) are known to promote the growth of beneficial gut bacteria, stimulate the immune system, and aid brain development.

Market Dynamics:

Growing awareness regarding health benefits of human milk oligosaccharides is expected to drive market growth. Additionally, increasing use of HMOs in food supplements and functional food & beverage products is again projected to foster market growth. In May 2021, NewAge, Inc., announced the launch of Nutrifii Kids™ Chewable Multivitamin, a daily supplement for support of the healthy development and immune systems of children and adolescents.

On the other hand, growing awareness regarding breastfeeding and high cost of production is expected to restrict the growth of human milk oligosaccharides market.

Key features of the study:

  • This report provides in-depth analysis of the global human milk oligosaccharides market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global human milk oligosaccharides market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include ZuChem Inc., Merck & Co. Inc., Chr. Hansen Holding AS (Jennewein Biotechnologie GmbH), Royal FrieslandCampina NV, BASF, IFF (DuPont Nutrition & Health), Gnubiotics, Inbiose NV, Carbosynth Holdings Limited, and Royal DSM N.V
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global human milk oligosaccharides market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human milk oligosaccharides market

Detailed Segmentation:

  • Global Human Milk Oligosaccharides Market, By Application:
    • Infant Formula
    • Dietary Supplements
    • Functional Food and Beverage
  • Global Human Milk Oligosaccharides Market, By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo